These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1564574)

  • 1. Cost-benefit analysis of vaccine programs.
    Hocking B
    J Occup Med; 1992 Apr; 34(4):357-8. PubMed ID: 1564574
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A benefit-cost analysis of a childhood varicella vaccination programme.
    Preblud SR; Orenstein WA; Koplan JP; Bart KJ; Hinman AR
    Postgrad Med J; 1985; 61 Suppl 4():17-22. PubMed ID: 3939152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
    Brisson M; Edmunds WJ
    Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants.
    Berger SA; Ginsberg GM; Slater PE
    Isr J Med Sci; 1990 Feb; 26(2):74-80. PubMed ID: 2108102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
    Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
    Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons.
    Nichol KL; Nordin J; Mullooly J
    Vaccine; 2006 Mar; 24(10):1562-8. PubMed ID: 16300868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-benefit ratio of tick-borne encephalitis vaccination of French troops based in Kosovo].
    Desjeux G; Lemardeley P; Colin C; Pascal B; Labarère J
    Rev Epidemiol Sante Publique; 2001 Jun; 49(3):249-57. PubMed ID: 11427828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City].
    Liu ZG; Zhao SL; Zhang YX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Apr; 16(2):81-4. PubMed ID: 7781052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of hospital vaccination programs in North Carolina.
    Honeycutt AA; Coleman MS; Anderson WL; Wirth KE
    Vaccine; 2007 Feb; 25(8):1484-96. PubMed ID: 17156901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
    Suárez E; Smith JS; Bosch FX; Nieminen P; Chen CJ; Torvinen S; Demarteau N; Standaert B
    Vaccine; 2008 Sep; 26 Suppl 5():F29-45. PubMed ID: 18992380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global eradication of poliomyelitis: benefit-cost analysis.
    Bart KJ; Foulds J; Patriarca P
    Bull World Health Organ; 1996; 74(1):35-45. PubMed ID: 8653814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
    Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
    Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.